Important Information for Investors of ESSA Pharma Inc.: Rosen Law Firm Reminds of Upcoming Deadline
New York, NY, March 11, 2025 – Rosen Law Firm, a leading global investor rights law firm, reminds purchasers of ESSA Pharma Inc. (NASDAQ: EPIX) securities between December 12, 2023, and October 31, 2024, inclusive (the “Class Period”), of the important March 25, 2025 lead plaintiff deadline. The lawsuit seeks to recover damages for ESSA Pharma investors under the Securities Act of 1933 and the Securities Exchange Act of 1934.
Background
ESSA Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of rare and debilitating diseases. The company’s lead product candidate, EPI-589, is a novel, selective androgen receptor modulator (SARM) being developed for the treatment of Duchenne muscular dystrophy (DMD).
Allegations
The complaint alleges that during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) ESSA Pharma’s clinical trial data for EPI-589 did not support the company’s claims that the drug was effective in treating DMD; and (2) as a result, the company’s public statements were materially false and misleading at all relevant times.
Effect on Individual Investors
If you purchased ESSA Pharma securities during the Class Period and suffered a loss, you may be entitled to compensation. The lead plaintiff deadline in this action is March 25, 2025. The lead plaintiff is the investor with the largest financial interest in the relief sought by the class. If you wish to serve as the lead plaintiff, you must apply before this deadline. To join the class, you need to provide your contact information so that you can be informed about the case’s progress.
Effect on the World
The potential consequences of this lawsuit for the biopharmaceutical industry and investors are significant. If the allegations are proven, it could lead to increased scrutiny of clinical trial data and regulatory oversight in the sector. Furthermore, investors may become more cautious when considering investments in biotech companies, potentially affecting the industry’s growth and innovation.
Conclusion
Rosen Law Firm encourages investors to contact the firm before March 25, 2025, to discuss their potential role as a lead plaintiff in this action. The firm represents investors worldwide, and its expertise and experience in securities litigation ensures that you and your fellow class members recover maximum compensation. For more information, please visit
- Rosen Law Firm reminds investors of the March 25, 2025 lead plaintiff deadline for ESSA Pharma securities purchased between December 12, 2023, and October 31, 2024.
- The lawsuit alleges that ESSA Pharma made false and/or misleading statements regarding the effectiveness of its lead product candidate, EPI-589, for the treatment of DMD.
- Individual investors who purchased ESSA Pharma securities during the Class Period and suffered a loss may be entitled to compensation.
- The potential consequences of this lawsuit for the biopharmaceutical industry and investors could be significant, including increased scrutiny of clinical trial data and regulatory oversight, and increased caution among investors.
